Table 2

NAT1 and NAT2 genotype frequencies in hepatocellular carcinoma cases and controls

CasesControls
Genotypen(%)n(%)Odds ratio95% CI
NAT2genotype
NAT2*5/*6 3(2.0)3(1.4)
NAT2*5/*7 3(2.0)3(1.4)
NAT2*6/*6 8(5.3)16(7.6)
NAT2*6/*7 8(5.3)24(11.4)
NAT2*7/*7 5(3.3)9(4.2)
 Sum of “0”NAT2*4 27(17.9)55(26.0)1.0Reference
NAT2*4/*5  5(3.3)10(4.7)
NAT2*4/*6 45(29.8)51(24.2)
NAT2*4/*7 26(17.2)28(13.3)
 Sum of “one”NAT2*4 76(50.3)89(42.2)1.741.00–3.02
NAT2*4/*4 48(31.8)67(31.8)1.460.81–2.64
NAT1genotype
NAT1*4/*4 35(23.2)50(23.7)
NAT1*4/*3 7(4.6)4(1.9)
NAT1*4/*11 0(0.0)1(0.5)
NAT1*3/*3 5(3.3)0(0.0)
NAT1*3/*11 2(1.3)3(1.4)
 Sum of “0”NAT1*10 49(32.4)58(27.5)1.0Reference
NAT1*4/*10 70(46.4)103(48.8)
NAT1*3/*10 4(2.6)3(1.4)
NAT1*10/*11 0(0.0)2(1.0)
 Sum of “one”NAT1*10 74(49.0)108(51.2)0.810.50–1.31
NAT1*10/*10 28(18.6)45(21.3)0.740.40–1.35